FDA Panel Votes Against Drugs Said to Prevent Prostate
WEDNESDAY, Dec. 1 (HealthDay News) -- A U.S. Food and Drug
Administration advisory committee on Wednesday voted against
approving two drugs for the prevention of prostate cancer, the
third-highest cancer killer of men.
The panel voted 17-0, with one abstention, that the risks of
Merck's Proscar outweighed its benefits, according to the
Associated Press. And in a similar vote, the panel voted 14-2, with two abstentions, against GlaxoSmithKline's Avodart. Both drugs are already approved to treat enlarged prostates.
"In a setting like this, the onus is on the drug to be completely safe, and to show benefit, and I don't think it reached that level," said panel Chairman Dr. Wyndham Wilson, of the National Cancer Institute.
The FDA does not have to heed the advice of its advisory panels,
but it typically does.
Research presented to the panel by Merck and GlaxoSmithKline
showed a 25 percent decrease in the incidence of low-grade prostate
tumors among users of the drugs.
But concern that a small number of men taking the drugs actually
developed more aggressive tumors led the panelists to find that the
risk of aggressive tumors outweighed the benefit of reducing tumors
that are seldom fatal, the wire service reported.
FDA regulators already had several concerns about using the
medications for the prevention of prostate cancer, the
AP reported. For one thing, black men, who are at high risk
for the disease, were underrepresented in the clinical trials. "The
applicability to African-American men is not known due to marked
under-representation," the FDA's online review stated.
Blacks made up just 4 percent of Merck's patients and only 2
percent of Glaxo's patients, according to the
The panel of outside experts assembled by the FDA also discussed
the overall value of preventing low-grade tumors. According to the
FDA, more than three-quarters of the tumors the drugs prevent are
slow-growing, meaning they are non-aggressive and probably not
life-threatening for anyone with a life expectancy of less than 20
Also, slightly more aggressive tumors were seen in men taking
Avodart and Proscar, compared with those taking placebo pills,
according to the FDA. But the pharamaceutical companies say the
drugs simply make those tumors easier to detect because they shrink
The U.S. National Cancer Institute estimates that 217,730 men
will be diagnosed with prostate cancer this year and 32,050 men
will die of it.
For more on prostate cancer, visit the
U.S. National Library of Medicine.
Copyright © 2010
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.